CLAIMS

1. A composition comprising a therapeutically effective amount of at least one antibiotic and at least one phospholipid, for use in the treatment of chronic rhinosinusitis (CRS) in a subject, wherein the at least one phospholipid is represented by formula II, or a pharmaceutically acceptable salt or solvate thereof:



II

wherein:

R^5 is a saturated or unsaturated C_{11}, C_{12}, C_{13}, C_{14}, or C_{15} alkyl chain.

2. Use of a composition comprising a therapeutically effective amount of at least one antibiotic and at least one phospholipid, in the manufacture of a medicament for the treatment of chronic rhinosinusitis (CRS) in a subject, wherein the at least one phospholipid is represented by formula II, or a pharmaceutically acceptable salt or solvate thereof:



II

wherein:

R^5 is a saturated or unsaturated C_{11}, C_{12}, C_{13}, C_{14}, or C_{15} alkyl chain.

3. The composition of claim 1 or use of claim 2, wherein R^5 is a saturated or unsaturated C_{12}, C_{13}, or C_{14} alkyl chain.
4. The composition of claim 1 or use of claim 2, wherein R^5 is a saturated C_{11}, C_{12}, C_{13}, C_{14}, or C_{15} alkyl chain.

5. The composition of claim 1 or use of claim 2, wherein when R^5 is an unsaturated alkyl chain R^5 has between 1 to 3 double bonds having a *cis*-configuration, a *trans*-configuration, or a mixture of *cis*- and *trans*- configurations.
6. The composition of claim 1 or use of claim 2, wherein the phospholipid is dodecylphosphocholine, or a pharmaceutically acceptable salt or solvate thereof.
7. The composition of claim 1 or use of claim 2, wherein the phospholipid is tetradecylphosphocholine, or a pharmaceutically acceptable salt or solvate thereof.
8. The composition of claim 1 or use of claim 2, wherein the phospholipid and the antibiotic are administered to the subject simultaneously.
9. The use of claim 1, wherein the phospholipid and the antibiotic are to be administered to the subject sequentially.
10. The composition of claim 1 or use of claim 2, wherein a pharmaceutical composition comprising the phospholipid and the antibiotic are to be administered through a nasal sinus of the subject.
11. The composition or use of claim 10, wherein the pharmaceutical composition is a dry composition, an aerosolized composition or a liquid composition.
12. The composition or use of claim 10, wherein the pharmaceutical composition is to be administered to the subject via an inhaler, a syringe device, an aerosol device or a nebulizer.
13. The composition or use of claim 10, wherein the pharmaceutical composition is to be administered to the subject in combination with a steroid or an antifungal compound.
14. The composition of claim 1 or use of claim 2, further comprising examining the subject for improved sinus symptoms, a lowered volume of nasal fluid or post-nasal drip, a partial or complete removal of biofilm in a sinus, or a decreased appearance of inflammation in the sinus.
15. The composition of claim 1 or use of claim 2, wherein the composition disrupts pre-formed bacterial biofilm, prevents the formation of bacterial biofilm, or a combination of the foregoing.
16. The composition or use of claim 15, wherein the bacterium is present in a sinonasal passage of the subject.

17. The composition of claim 1 or use of claim 2, wherein the at least one antibiotic comprises gentamicin, tobramycin, or a combination of the foregoing.
18. A therapeutic kit or pharmaceutical composition for use in the treatment of chronic rhinosinusitis (CRS), comprising at least one antibiotic and at least one phospholipid, wherein the phospholipid is represented by formula II, or a pharmaceutically acceptable salt or solvate thereof:



II

wherein:

R^5 is a saturated or unsaturated C_{11}, C_{12}, C_{13}, C_{14}, or C_{15} alkyl chain

or pharmaceutically acceptable salts or solvate thereof.

19. Use of a therapeutic kit or pharmaceutical composition in the manufacture of a medicament for the treatment of chronic rhinosinusitis (CRS), wherein the therapeutic kit or pharmaceutical composition comprises at least one antibiotic and at least one phospholipid, wherein the phospholipid is represented by formula II, or a pharmaceutically acceptable salt or solvate thereof:



II

wherein:

R^5 is a saturated or unsaturated C_{11}, C_{12}, C_{13}, C_{14}, or C_{15} alkyl chain

or pharmaceutically acceptable salts or solvate thereof.

20. The kit or composition of claim 18, or the use of claim 19, wherein the at least one phospholipid is dodecylphosphocholine, or a pharmaceutically acceptable salt or solvate thereof, or tetradecylphosphocholine, or a pharmaceutically acceptable salt or solvate

thereof, and the at least one antibiotic comprises one or both of gentamicin and tobramycin.

21. The kit or composition of claim 18, or the use of claim 19, wherein R^5 is a saturated C_{11}, C_{12}, C_{13}, C_{14}, or C_{15} alkyl chain.
22. The kit or composition of claim 18, or the use of claim 19, wherein R^5 is a saturated or unsaturated C_{12}, C_{13}, or C_{14}, alkyl chain.
23. The kit or composition of claim 18, or the use of claim 19, wherein when R^5 is an unsaturated alkyl chain R^5 has between 1 to 3 double bonds having a *cis*-configuration, a *trans*-configuration, or a mixture of *cis*- and *trans*- configurations.
24. The kit or composition of claim 18, or the use of claim 19, wherein the at least one antibiotic comprises gentamicin, tobramycin, or a combination of the foregoing.